Results show that oral administration of the company’s TREX1 inhibitors reduced tumor growth in an animal model of colorectal cancer and at the same time increased the recruitment of immune cells to the tumors.
“Targeting TREX1 represents a novel approach to amplifying the immune response, with a mechanism that is different from existing approved immunotherapies. When blocking TREX1 in tumors, the body's immune response is reactivated, resulting in inhibition of tumor growth. Our data support the therapeutic hypothesis in this program, and we look forward to presenting the program to scientists and potential partners in the immuno-oncology field.” said
New publications show that the function of the TREX1 protein in cancer cells inhibits the immune response. This, in combination with the company's data, confirms the hypothesis that TREX1 is an interesting new target for cancer therapy.
The poster "Inhibition of TREX1 Increases Interferon Signaling and Reduces Tumor Growth In Vivo" is presented by Camilla Silvander, PhD, Director Protein Science,
© Modular Finance, source